drugset / Trial / NCT01057264
HAI Abraxane With Gemcitabine and Bevacizumab
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of Abraxane® (nab-paclitaxel) when given directly into the liver, in combination with Gemzar® (gemcitabine) and Avastin® (bevacizumab) when given by vein.
Timeline
- Start
- 2010-01
- Primary completion
- 2014-05
- Completion
- 2014-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |
| Subject | Gemcitabine | Small molecule | 600 mg/m2 | Intravenous |
| Subject | Nab-paclitaxel | Small molecule | 120 mg/m2 | Other |
| Background | filgrastim | Protein / enzyme biologic | 5 ug/kg | Subcutaneous |